Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, shares some insights into a study which evaluated the use of mass spectrometry and next-generation flow (NGF) to analyze measurable residual disease (MRD) and long-term disease control in patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.